Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 11851484
APP PUB NO 20210246200A1
SERIAL NO

17124930

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to antibodies binding to human interleukin-2 (hIL-2). The invention more specifically relates to humanized antibodies specifically binding a particular epitope of hIL-2 and, when bound to this epitope, displaying a unique capability of inhibiting binding of hIL-2 to CD25.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
UNIVERSITAT ZURICH8006 ZÜRICH

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Arenas-Ramirez, Natalia Zürich, CH 5 25
Beuvink, Iwan Basel, CH 7 110
Boyman, Onur Küsnacht, CH 9 36
Brannetti, Barbara Basel, CH 25 465
Katopodis, Andreas Basel, CH 14 58
Popp, Simone Basel, CH 2 15
Regnier, Catherine Basel, CH 8 41
Zou, Chao Basel, CH 50 296

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Jun 26, 2027
7.5 Year Payment $3600.00 $1800.00 $900.00 Jun 26, 2031
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jun 26, 2035
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00